Insulin Enhances Nitric Oxide Production in Trabecular Meshwork Cells via De Novo Pathway for Tetrahydrobiopterin Synthesis

Jae Woo Kim

doi:10.3341/kjo.2007.21.1.39

Korean J Ophthalmol > Volume 21(1); 2007 > Article

Kim: Insulin Enhances Nitric Oxide Production in Trabecular Meshwork Cells via De Novo Pathway for Tetrahydrobiopterin Synthesis

Original Article

Korean Journal of Ophthalmology : KJO 2007;21(1):39-44.

Published online: March 20, 2007

DOI: https://doi.org/10.3341/kjo.2007.21.1.39

Insulin Enhances Nitric Oxide Production in Trabecular Meshwork Cells via De Novo Pathway for Tetrahydrobiopterin Synthesis

Jae Woo Kim, MD

Department of Ophthalmology, Catholic University of Daegu College of Medicine, Daegu, Korea.

Reprint requests to Jae Woo Kim, MD. Department of Ophthalmology, Catholic University of Daegu College of Medicine, 3056-6 Daemyeung-4dong, Nam-gu, Daegu 705-718, Korea.
Tel: 82-53-650-4728, Fax: 82-53-627-0133, jwkim@cu.ac.kr

Received August 02, 2006 Accepted January 30, 2007

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To investigate the effect of insulin on the production of nitric oxide (NO) in the trabecular meshwork (TM) cells and the enzymatic synthetic pathway of tetrahydrobiopterin (BH₄) synthesis.

Methods

Primarily cultured human TM cells were exposed to 1, 10, and 100 µg/ml of insulin and 0, 1, 10, 100 and 1000 nM dexamethasone for 3 days. To evaluate the enzymatic pathway of BH₄ synthesis, 10 µM dexamethasone, 5 mM diaminopyrimidinone, 100 µM ascorbic acid, 100 µM sepiapterin, or 10 µM methotrexate were also co-administered respectively. Cellular survival and NO production were measured with MTT and Griess assay.

Results

Insulin enhanced NO production in a dose-dependent manner significantly (p<0.05) without affecting cell viability, whereas dexamethasone inhibited NO production. With co-exposure of insulin, diaminopyrimidinone and sepiapterin inhibited insulin-induced NO production. Ascorbic acid increased NO production independent of insulin and methotrexate did not affect to the action of insulin in NO production.

Conclusions

Insulin increases NO production in TM cells via de novo synthetic pathway for BH₄ synthesis. Insulin could be involved in the regulation of trabecular outflow by enhancing NO production in TM cells.

Keywords: Dexamethasone, Insulin, Nitric oxide, Tetrahydrobiopterin, Trabecular meshwork cell

Nitric oxide (NO) is a short-lived free radical, generated from L-arginine by NO synthase (NOS) in an enzymatic reaction. It is diffusible across the biological membrane and has such diverse roles as an endothelium derived relaxing factor, a neuromodulator, and an immunological mediator in the cardiovascular, nervous, and immune systems.1,2 In the eye, NO is a physiological regulator as well as a pathological mediator not only in the vascular system but also in other tissues including the retina and the ocular surface.3

It has been proposed that the pathogenesis of primary open-angle glaucoma may be related to the alteration in the trabecular meshwork (TM), the ocular tissue believed to be responsible for the majority of aqueous humor outflow resistance. TM cells perform a variety of activities in maintaining the normal function of the aqueous outflow pathway.

The activity of nitric oxide synthase has been shown in the TM of bovine, porcine and human eyes.4-6 Since TM possess a contractile properties and the main isoform of NOS in the ocular outflow pathway is known to an eNOS,4 NO can affect outflow facility by relaxation of TM. It is also known that NO is involved in the regulation of trabecular outflow and external administration of NO results in decreased IOP.7,8 Alteration of NOS activity is reported in the glaucomatous eyes9 and basal NO production is enhanced by hydraulic pressure in cultured human TM cells.10

Endothelial dysfunction is characterized by an inability of endothelial cells to produce adequate amount of bioactive NO and hyperglycemia contributes to endothelial dysfunction and decreased NO bioavailability11,12 but the mechanisms remain uncharacterized. It has been proposed that high glucose inhibits basal eNOS expression, activity, and NO production in cultured endothelial cells.13,14 Insulin is a direct-acting vasodilator in intact vessels and has been demonstrated to stimulate NO production in cultured endothelial cells.15-17

Taken together, there is a possibility that insulin can affect on the formation of NO in TM cells. The present study was designed to investigate whether insulin affect NO production in human TM cells. Additionally the enzymatic synthetic pathway for tetrahydrobiopterin (BH₄) synthesis, an essential cofactor for NO synthesis, was also evaluated.

Materials and Methods

Cell culture

TM cell cultures were established from enucleated human eyes obtained from an eye bank and transported on ice within 2 hr after exsanguinations as previously described.18,19 Briefly, TM tissues were excised by dissecting a continuous strand of tissue between the line of Schwalbe and the scleral spur, using a curette to separate a continuous strand of TM tissue away from the scleral spur, ciliary muscle and Schwalbe's line. The excised TM tissues were placed in the sterile laminin-coated culture dish with DMEM medium containing 15% fetal bovine serum, 2 mM glutamine, 50 µg/ml gentamicin and 2.5 mg/ml fungizone and left undisturbed for 3 to 5 days in a 37℃ incubator with a 5% CO₂ atmosphere. After identifying initial cell growth, the explants were removed and the cultures were maintained with a medium containing 10% fetal bovine serum. Passages three through five were used for experiments.

Experimental treatment

With approaching confluency, the cultures were trypsinized and inoculated into 24 well culture plates (1×10⁶ cells/well). After allowing 24 hours for attachment, 1, 10, 100, and 1000 nM of dexamethasone (Sigma, St. Louis, MO, USA) and 1, 10, and 100 µg/ml of insulin (Sigma, St. Louis, MO, USA) were added to the media with or without NOS inhibitor, 0.5 mM N^ω-Nitro-L-arginine methyl ester (L-NAME: Sigma, St. Louis, MO, USA). In addition, 10 µM dexamethasone, 5 mM diaminopyrimidinone, 100 µM L-ascorbic acid, 100 µM sepiapterin, or 10 µM methotrexate were added to the medium respectively with co-exposure of insulin to evaluate enzymatic synthetic pathway of BH₄ synthesis. The cultures were replaced to the incubator and incubated for 72 hours.

Cell viability

Cell viability was determined by a rapid colorimetric assay using 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT: Sigma, St Louis, MO, USA). The MTT assay is based on the ability of the tetrazolium salt MTT to detect living but not dead cells. The signal generated, optical density (OD) is directly proportional to the number of cells.20,21 After adding 100 µl of an MTT stock solution (5 mg MTT/ml PBS) to each well, the media was completely removed from the well after a 4-hr incubation at 37℃. Then 0.5 ml of dimethyl sulfoxide (DMSO: Sigma, St Louis, MO, USA) was added to each well and 100 µl of the solution from each well was transferred to a 96-well plate and read at 570 nm on a multi-well scanning spectrophotometer. It was noted that a minimum 10 min exposure to DMSO was required to dissolve the MTT formazan crystals after which the absorbance remained constant for 20 min. Thus, in all experiments spectrophotometric readings were taken 15 min after the addition of DMSO.

Measurement of NO production

Nitrite's concentrations in the media were measured by Griess reaction.22 Briefly, media samples were collected from each wells following appropriate treatment and reacted with modified Griess reagent (Sigma, St Louis, MO, USA) by mixing equal volumes with each other at room temperature for 15 min. Optical density was then measured and read on a multi-well scanning spectrophotometer at 540 nm. The nitrite concentration was then determined from a comparison of absorbance with that of a standard solution of sodium nitrite in medium. The background absorbance measured using the medium alone, was subtracted from all values.

Statistical analysis

Data are expressed as mean±standard error of the mean (mean±SEM) corresponding to the number of wells analyzed. Experimental differences between control culture results and a single treatment group were evaluated using Student's t-test with P values less than 0.05 considered significant.

Results

Cell culture

The cultured human TM cells were similar in appearance to those human TM cells generated by other investigator and identification of TM cells was done by their characteristic morphology and growth pattern.18,19 Confluent cultures of TM cells grew as a monolayer of closely packed cells with branching cell bodies making multiple contacts between cells. The cells were flattened with rounded to moderately elongated bodies with each cell containing a centrally placed nucleus. Often the migrating TM cells showed ruffled borders as they detached from the main cell mass. Occasionally migrating cells formed satellite colonies of cells with identical morphology to the main cell mass.18,19 This cellular morphology was maintained at least for 5 passages.

Effect on cell viability

Insulin and dexamethsone did not affect significantly on the survival of cultured trabecular meshwork cells up to 100 µg/ml and 1000 nM respectively. Other co-exposed chemical agents also did not affect cellular survival (data not shown). Thus the effect on NO production of the each chemical agent used at experiments does not influenced by cell numbers significantly.

Effect on NO production

The synthetic glucocorticoid dexamethasone inhibited NO production significantly in a dose-dependent manner. Nitrite concentration was decreased from 1.60 µM of non-exposed control down to 0.89 µM of 1000 nM dexamethasone exposure (Fig. 1). On the contrary, insulin enhanced NO production significantly in a dose-dependent manner up to 2.76 µM (Fig. 2). This insulin-induced enhanced NO production was inhibited by L-NAME, indicating NO was produced by TM cells per se. With co-exposure of insulin, 10 µM dexamethasone did not affect to the insulin-induced increase of NO production (Fig. 3).

Co-exposure of 5 mM diaminopyrimidinone and 100 µM sepiapterin, inhibitors of de novo synthetic pathway for BH₄ synthesis, inhibited the insulin-induced increase of NO production (Fig. 4, 5). But co-exposure of 100 µM L-ascorbic acid, a stimulator of de novo synthetic pathway for BH₄ synthesis, increased NO production independent of the co-exposure of insulin (Fig. 6). Compared to single exposure of 0, 1, 10, and 100 µg/ml, co-exposure of 100 µM L-ascorbic further increased NO production 84%, 109.1%, 92.6%, and 103.3% respectively. Co-exposure of 10 µM methotreaxate, an inhibitor of salvage pathway for BH₄ synthesis, decreased overall NO production but did not affect to the insulin-induced increase of NO production (Fig. 7). Compared to single exposure of 0, 1, 10, and 100 µg/ml, co-exposure of 10 µM methotrexate further decreased NO production 56.9%, 54.6%, 77.8%, and 70.9% respectively. These findings suggest that insulin increases NO production via enhancing de novo synthetic pathway for BH₄ synthesis in cultured TM cells.

Discussion

The main findings of this study are 1) dexamethasone inhibited NO production; 2) insulin enhanced NO production; and 3) enzymatic pathway of insulin-induced enhanced NO production is via stimulating de novo synthetic pathway for BH₄ synthesis.

Since TM cells possess endothelial-like, smooth muscle cell-like activities, and NOS activities are expressed trabecular outflow pathway,4 NO could affect on the outflow facility by regulating the contractility TM. The concentration of endothelin, one of the most potent vasoconstrictors, which counteracts with NO,23 is increased in patients with progressive open angle glaucoma.24 In addition, NO possesses antiplatelet aggregatory activity and decreases leukocyte adhesion.1,3 Several studies have shown that NO is involved in the regulation of intraocular pressure and suggest that NO could increase the trabecular outflow by its innate dilating activity, thus result in the relaxation of TM and decrease of intraocular pressure. Recent findings have demonstrated that NO can serve as an ocular hypotensive agent.7,25-29 The NO/guanylate cyclase system plays a role in aqueous humor dynamics and in the regulation of intraocular pressure.30

In endothelial cells, high glucose inhibits NO production and result in oxidative stress subsequently.11-13 In the present study, a synthetic glucocorticoid dexamethasone decreased NO production in a dose-dependent manner in TM cells. Activity of eNOS can be modified in disease states, and in diabetes hyperglycemia inhibits eNOS as a result of a posttranslational modification at the protein kinase Akt regulatory site.14 Clinically such inhibition of NO production by glucose may be associated with increased intraocular pressure in steroid-induced glaucoma or diabetes (the concentration of glucose in the aqueous humor is higher in diabetes).31 Endothelin-1 expression was also induced by glucose32 and was increased in diabetes.33 On the contrary, insulin promotes vasodilatation by enhancing NO production in endothelial cells.15-17 As in the endothelial cells, insulin also increased NO production in TM cells in a dose-dependent manner in the present study, suggesting the beneficial effect of insulin on the regulation of trabecular outflow by relaxation activity of NO in TM.

The gasotransmitter NO is synthesized by oxidation of L-arginine and many cofactors are involved in the synthesis of NO. Among them, the pteridine cofactor BH₄ has emerged as a critical determinant of NOS activity.34 BH₄ is an essential cofactor for the proper flow of electrons to oxidize L-arginine, and NOS is the only heme-containing enzyme known to require a pterin cofactor for activity. Of significant interest, therefore, is that a reduced availability of BH₄ may be a key factor in the etiology of the endothelial dysfunction. BH₄ synthesis occurs via two distinct pathways: a de novo synthetic pathway which uses GTP as a precursor and a salvage pathway for preexisting dihydropterins.35 To evaluate the enzymatic synthetic pathway for BH₄ synthesis involved in the insulin-induced enhanced NO production in TM cells, several inhibitors and stimulators of BH₄ synthesis were tested in this study. Insulin's enhancing action on the NO production did not affected by dexamethsone, a known inhibitor of de novo synthetic pathway for BH₄ synthesis. This finding suggests insulin could overwhelm the inhibitory action of dexamethasone on the NO production. However insulin's enhancing action on the NO production was markedly abolished by diaminopyrimidinone, another known inhibitor of de novo synthetic pathway for BH₄ synthesis. Sepiapterin, acts as an inhibitor of de novo synthetic pathway for BH₄ synthesis if not stimulated, also abolished insulin's enhancing action on the NO production.

Recently, several studies have shown that ascorbic acid, a stimulator of de novo synthetic pathway for BH₄ synthesis, potentiates endothelial NO synthesis in a dose-time-dependent fashion36 and may protect NO from inactivation via chemical stabilization of BH₄ in endothelial cells.37,38 Although ascorbic acid increased NO synthesis in this study, it abolished insulin's enhancing action on the NO production. Furthermore methotrexate, an inhibitor of salvage pathway for BH₄ synthesis, markedly inhibited NO production despite of insulin's enhancing action on the NO production. These findings suggest that insulin enhances NO production in cultured human TM cells via de novo pathway of BH₄ synthesis and ovewhelms the inhibitory action of glucocorticoid on the BH₄-dependent endothelial function.

Preservation of the bioavailability of NO should be considered significant in the TM since NO is known to a cellular mediator that can modulate vascular tone as well as aqueous humor dynamic in the eye.39 Beside from its role in the regulation of trabecular outflow, another possible roles of NO also could be considered. The tissues facing the anterior chamber of the eye are exposed constantly to aqueous containing reactive oxygen products generated by light-catalyzed reactions. Such radicals may cause increased oxidation in tissues of the anterior eye segment and finally lead to oxidative damage. Oxidative stress that exceeds the capacity of the TM for detoxification could result in damage of TM cells and subsequent alteration of aqueous outflow resistance. Oxidative stress induces unavailability of BH₄ and causes NOS to generate reactive oxygen substances. This will result both in NO depletion, and in peroxynitrite-dependent oxidation of BH₄. Probably the resultant oxidative stress causes TM cell damage. Previous studies demonstrated decreased antioxidant potential of aqueous humor40,41 and increased oxidative DNA damage in the glaucomatous eyes.42,43 Chronic oxidative stress-induced TM cell damage has been suggested as an another possible pathogenetic mechanism of glaucoma recently.44

Recent report demonstrated the increased cellular senescence in the outflow pathway of glaucomatous eyes.45,46 Chronic oxidative stress, which resulted from NO dysregulation, also can provoke cellular senescence including TM cells.47,48 High glucose is known to cause cellular senescence and NO can delay cellular senescence caused by chronic oxidative stress.49,50 Thus the possible significance of preserving the bioavailability of NO in TM includes not only maintain trabecular outflow but also decrease oxidative stress, hence delay cellular senescence. Additional studies should focus on determining the most effective therapeutic approach for preventing oxidative stress and reducing the development and/or progression of glaucomatous optic neuropathy.

In summary, NO could decrease chronic oxidative stress of TM and delay aging of TM cells. This study suggests that insulin might play for a role in the maintenance of TM function by enhancing NO production via de novo pathway of BH₄ synthesis. Further studies will be required to ascertain such roles of NO in TM.

REFERENCES

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.

2. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994;63:175-195.

3. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. Surv Ophthalmol 1997;42:71-82.

4. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway. Invest Ophthalmol Vis Sci 1995;36:1765-1773.

5. Geyer O, Podos SM, Mittag T. Nitric oxide synthase activity in tissues of the bovine eyes. Graefes Arch Clin Exp Ophthalmol 1997;235:786-793.

6. Meyer P, Champion C, Schlotzer-Schrehardt U, et al. Localization of nitric oxide synthase isoforms in porcine ocular tissues. Curr Eye Res 1999;18:375-380.

7. Schuman JS, Erickson K, Nathanson JA. Nitrovasodilator effects on intraocular pressure and ocular facility in monkeys. Exp Eye Res 1994;58:99-105.

8. Wana RF, Podos SM. Effect of the topical application of nitroglycerin on intraocular pressure in normal and glaucomatous monkeys. Exp Eye Res 1995;60:337-339.

9. Nathanson JA, McKee M. Alteration of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 1995;36:1774-1784.

10. Matsuo T. Basic nitric oxide production is enhanced by hydraulic pressure in cultured human trabecular cells. Br J Ophthalmol 2000;84:631-635.

11. Brodsky SV, Morrishow AM, Dharia N, et al. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001;280:F480-F486.

12. Kimura C, Oike M, Koyama T, et al. Impairment of endothelial nitric oxide production by acute glucose overload. Am J Physiol Endocrinol Metab 2001;280:E171-E178.

13. Ding Y, Vaziri ND, Coulson R, et al. Effects of simulated hyperglycemia, insulin, and glucagons on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab 2000;279:E11-E17.

14. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001;198:1341-1348.

15. Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-2515.

16. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1174.

17. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by Wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894-898.

18. Polansky JR, Weinreb RN, Baxter JD, et al. Human trabecular cells I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci 1979;18:1043-1049.

19. Polansky JR, Wood IS, Maglio MT, et al. Trabecular meshwork cell culture in glaucoma research: Evaluation of biological activity and structural properties of human trabecular meshwork cells in vitro. Ophthalmology 1984;91:580-595.

20. Kahler CM, Heroid M, Reinisch N, et al. Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts. J Cell Physiol 1996;166:601-608.

21. Gomm JJ, Coope RC, Browne PJ, et al. Separated human breast epithelial and myoepithelial cells have different growth factor requirements in vitro but can reconstitute normal breast lobuloalveolar structure. J Cell Physiol 1997;171:11-19.

22. Green LC, Wagner DA, Glogowski J, et al. Analysis of Nitrate, Nitrite and [15N]Nitrate in biologic fluids. Anal Biochem 1982;126:131-138.

23. Haefliger IO, Dettmann E, Liu R, et al. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv Ophthalmol 1999;43:S51-S58.

24. Emre M, Orgül S, Shaw SG, et al. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol 2005;89:60-63.

25. Becker B. Topical 8-bromo-cyclic GMP lowers intraocular pressure. Invest Ophthalmol Vis Sci 1990;31:1647-1649.

26. Nathanson JA. Nitrovasidilators as a new class of ocular hypotensive agents. J Pharmacol Exp Ther 1991;260:956-965.

27. Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 1994;35:2515-2520.

28. Francine FB-C, Oliver G, Francois D'H, et al. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest Ophthalmol Vis Sci 1996;37:1711-1715.

29. Kojima S, Sugiyama T, Shimizu K, et al. Effect of a nitric oxide donor on intraocular pressure. Nippon Ganka Gakkai Zasshi 1996;100:181-186.

30. Schneemann A, Dijkstra BG, van den Berg TJ, et al. Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion. Graefes Arch Clin Exp Ophthalmol 2002;240:936-941.

31. Davies PD, Duncan G, Pynsent PB, et al. Aqueous humour glucose concentration in cataract patients and it effect on lens. Exp Eye Res 1984;39:605-609.

32. Park JY, Takahara N, Gabriele A, et al. Unduction of endothelin-1 expression by glucose An effect of protein kinase C activation. Diabetes 2000;49:1239-1248.

33. Cardillo C, Campia U, Bryant MB, et al. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002;106:1783-1787.

34. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004;24:413-420.

35. Gross SS, Levi R. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced intric oxide generation by vascular smooth muscle. J Biol Chem 1991;36:25722-25729.

36. Heller R, Munscher-Pailug F, Grabner R, et al. L-ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem 1999;274:8254-8260.

37. Huang A, Vita JA, Venema RC, et al. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000;275:17399-17496.

38. Heller R, Unbehaun A, Schnellenberg B, et al. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001;276:40-47.

39. Chiou GCY. Review: effects of nitric oxide on eye disease and their treatment. J Ocul Pharmaco Ther 2001;17:189-198.

40. Ferreira SM, Lerner SF, Brunzini R, et al. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004;137:62-69.

41. Yildirim O, Ates NA, Ercan B, et al. Role of oxidative stress enzymes in open-angle glaucoma. Eye 2005;19:580-583.

42. Izzotti A, Sacca SC, Cartiglia C, et al. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003;114:638-646.

43. Sacca S, Pascotto A, Camicione P, et al. Oxidative DNA damage in human trabecular meshwork. Arch Ophthalmol 2005;123:458-463.

44. Sacca S. Nitric oxide as a mediator of glaucoma pathogenesis. Med Sci Monit 2002;8:LE33-LE34.

45. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res 2005;24:612-637.

46. Liton PB, Challa P, Stinnett S, et al. Cellular senescence in the glaucomatous outflow pathway. Exp Gerontol 2005;40:745-748.

47. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002;27:339-344.

48. Kurz DJ, Decary S, Hong Y, et al. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004;117:2417-2426.

49. Blazer S, Khankin E, Segev Y, et al. High glucose-induced replicative senescence: point of no return and effect on telomerase. Biochem Biophy Res Comm 2002;296:93-101.

50. Vasa M, Breitchopf K, Zeiher AM, et al. NO activates telomerases and delays endothelial cell senescence. Circ Res 2000;87:540-542.

Fig. 1

Effect of dexamethasone on the production of nitric oxide in cultured trabecular meshwork cell exposed for 3 days. Dexamethasone decreased nitric oxide production. (*; p<0.05)

Fig. 2

Effect of insulin on the production of nitric oxide on cultured human trabecular meshwork cells. Insulin increased nitric oxide production in a dose-dependent manner and inhibited by 0.5 mM L-NAME (N^ω-Nitro-L-arginine methyl ester). (*; p<0.05)

Fig. 3

Effect of 10 µM dexamethasone on the production of nitric oxide after co-exposure to insulin. Dexamethasone did not affect insulin-induced production of nitric oxide significantly. (*; p<0.05)

Fig. 4

Effect of 5 mM diaminopyrimidinone on the production of nitric oxide after co-exposure to insulin. Diaminopyrimidionone abolished insulin-induced production of nitric oxide. (p>0.05 at each group)

Fig. 5

Effect of 100 µM sepiapterin on the production of nitric oxide after co-exposure to insulin. Sepiapterin abolished insulin-induced production of nitric oxide. (p>0.05 at each group)

Fig. 6

Effect of 100 µM Lascorbic on the production of nitric oxide after co-exposure to insulin. L-ascorbic acid increased nitric oxide production and abolished insulin-induced production of nitric oxide. (p>0.05 at each group)

Fig. 7

Effect of 100 µM methotrexate on the production of nitric oxide after co-exposure to insulin. Methotrexate did not affect insulin-induced production of nitric oxide significantly. (*; p<0.05)